Intellia Therapeutics (NTLA) Other Gross PP&E Adjustments (2016 - 2025)
Intellia Therapeutics (NTLA) has disclosed Other Gross PP&E Adjustments for 11 consecutive years, with -$55.7 million as the latest value for Q4 2025.
- On a quarterly basis, Other Gross PP&E Adjustments rose 68.53% to -$55.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$55.7 million, a 68.53% increase, with the full-year FY2025 number at -$55.7 million, up 68.53% from a year prior.
- Other Gross PP&E Adjustments was -$55.7 million for Q4 2025 at Intellia Therapeutics, up from -$120.6 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of -$5.5 million in Q2 2021 to a low of -$177.0 million in Q4 2024.
- A 5-year average of -$92.5 million and a median of -$103.6 million in 2022 define the central range for Other Gross PP&E Adjustments.
- Peak YoY movement for Other Gross PP&E Adjustments: soared 78.28% in 2021, then tumbled 1297.48% in 2022.
- Intellia Therapeutics' Other Gross PP&E Adjustments stood at -$35.2 million in 2021, then crashed by 168.67% to -$94.5 million in 2022, then increased by 22.55% to -$73.2 million in 2023, then plummeted by 141.99% to -$177.0 million in 2024, then surged by 68.53% to -$55.7 million in 2025.
- Per Business Quant, the three most recent readings for NTLA's Other Gross PP&E Adjustments are -$55.7 million (Q4 2025), -$120.6 million (Q3 2025), and -$131.8 million (Q2 2025).